Literature DB >> 34223160

Synthesis and evaluation of pyridine-derived bedaquiline analogues containing modifications at the A-ring subunit.

Lisa Barbaro1, Gayathri Nagalingam2, James A Triccas2, Lendl Tan3,4, Nicholas P West3,4, Jonathan B Baell1, Daniel L Priebbenow5.   

Abstract

Despite promising efficacy, the clinical use of the anti-tubercular therapeutic bedaquiline has been restricted due to safety concerns. To date, limited SAR studies have focused on the quinoline ring (A-ring), and as such, we set out to explore modifications within this region in an attempt to discover new bedaquiline variants with an improved safety profile. We herein report the development of unique synthetic strategies that facilitated access to novel bedaquiline analogues leading to the discovery that anti-tubercular activity could be retained following replacement of the quinoline motif with pyridine heterocycles. This discovery is anticipated to open up multiple new avenues for exploration in the design of improved anti-tubercular therapeutics. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 34223160      PMCID: PMC8221263          DOI: 10.1039/d1md00063b

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  30 in total

1.  Infectious disease. Approval of novel TB drug celebrated--with restraint.

Authors:  Jon Cohen
Journal:  Science       Date:  2013-01-11       Impact factor: 47.728

2.  Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207.

Authors:  Jerome Guillemont; Christophe Meyer; Alain Poncelet; Xavier Bourdrez; Koen Andries
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

Review 3.  Synthetic approaches towards bedaquiline and its derivatives.

Authors:  Matthew B Calvert; Daniel P Furkert; Christopher B Cooper; Margaret A Brimble
Journal:  Bioorg Med Chem Lett       Date:  2020-04-07       Impact factor: 2.823

Review 4.  QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.

Authors:  Maurizio Recanatini; Elisabetta Poluzzi; Matteo Masetti; Andrea Cavalli; Fabrizio De Ponti
Journal:  Med Res Rev       Date:  2005-03       Impact factor: 12.944

Review 5.  Unique structural and mechanistic properties of mycobacterial F-ATP synthases: Implications for drug design.

Authors:  Neelagandan Kamariah; Priya Ragunathan; Joon Shin; Wuan-Geok Saw; Chui-Fann Wong; Thomas Dick; Gerhard Grüber
Journal:  Prog Biophys Mol Biol       Date:  2019-11-16       Impact factor: 3.667

6.  Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility.

Authors:  Chee Wei Ang; Lendl Tan; Melissa L Sykes; Neda AbuGharbiyeh; Anjan Debnath; Janet C Reid; Nicholas P West; Vicky M Avery; Matthew A Cooper; Mark A T Blaskovich
Journal:  J Med Chem       Date:  2020-11-05       Impact factor: 7.446

7.  Nontoxic Metal-Cyclam Complexes, a New Class of Compounds with Potency against Drug-Resistant Mycobacterium tuberculosis.

Authors:  Mingfeng Yu; Gayathri Nagalingam; Samantha Ellis; Elena Martinez; Vitali Sintchenko; Malcolm Spain; Peter J Rutledge; Matthew H Todd; James A Triccas
Journal:  J Med Chem       Date:  2016-06-07       Impact factor: 7.446

8.  Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.

Authors:  Elin M Svensson; Stephen Murray; Mats O Karlsson; Kelly E Dooley
Journal:  J Antimicrob Chemother       Date:  2014-12-21       Impact factor: 5.790

9.  Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles.

Authors:  Hamish S Sutherland; Amy S T Tong; Peter J Choi; Daniel Conole; Adrian Blaser; Scott G Franzblau; Christopher B Cooper; Anna M Upton; Manisha U Lotlikar; William A Denny; Brian D Palmer
Journal:  Bioorg Med Chem       Date:  2018-02-20       Impact factor: 3.641

10.  Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units.

Authors:  Peter J Choi; Hamish S Sutherland; Amy S T Tong; Adrian Blaser; Scott G Franzblau; Christopher B Cooper; Manisha U Lotlikar; Anna M Upton; Jerome Guillemont; Magali Motte; Laurence Queguiner; Koen Andries; Walter Van den Broeck; William A Denny; Brian D Palmer
Journal:  Bioorg Med Chem Lett       Date:  2017-10-20       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.